These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
387 related items for PubMed ID: 2174343
1. Receptors for luteinizing hormone-releasing hormone (LHRH) in Dunning R3327 prostate cancers and rat anterior pituitaries after treatment with a sustained delivery system of LHRH antagonist SB-75. Srkalovic G, Bokser L, Radulovic S, Korkut E, Schally AV. Endocrinology; 1990 Dec; 127(6):3052-60. PubMed ID: 2174343 [Abstract] [Full Text] [Related]
2. Chronic administration of the luteinizing hormone-releasing hormone (LHRH) antagonist cetrorelix decreases gonadotrope responsiveness and pituitary LHRH receptor messenger ribonucleic acid levels in rats. Pinski J, Lamharzi N, Halmos G, Groot K, Jungwirth A, Vadillo-Buenfil M, Kakar SS, Schally AV. Endocrinology; 1996 Aug; 137(8):3430-6. PubMed ID: 8754771 [Abstract] [Full Text] [Related]
3. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice. Redding TW, Schally AV, Radulovic S, Milovanovic S, Szepeshazi K, Isaacs JT. Cancer Res; 1992 May 01; 52(9):2538-44. PubMed ID: 1568223 [Abstract] [Full Text] [Related]
4. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Fekete M, Bajusz S, Groot K, Csernus VJ, Schally AV. Endocrinology; 1989 Feb 01; 124(2):946-55. PubMed ID: 2536323 [Abstract] [Full Text] [Related]
6. Regression of nitrosamine-induced pancreatic cancers in hamsters treated with luteinizing hormone-releasing hormone antagonists or agonists. Szende B, Srkalovic G, Groot K, Lapis K, Schally AV. Cancer Res; 1990 Jun 15; 50(12):3716-21. PubMed ID: 2160323 [Abstract] [Full Text] [Related]
7. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model. Yano T, Pinski J, Szepeshazi K, Milovanovic SR, Groot K, Schally AV. Prostate; 1992 Jun 15; 20(4):297-310. PubMed ID: 1351672 [Abstract] [Full Text] [Related]
9. Effect of treatment with LHRH analogs containing cytotoxic radicals on the binding characteristics of receptors for luteinizing-hormone-releasing hormone in MXT mouse mammary carcinoma. Milovanovic SR, Monje E, Szepeshazi K, Radulovic S, Schally A. J Cancer Res Clin Oncol; 1993 Jun 15; 119(5):273-8. PubMed ID: 8382705 [Abstract] [Full Text] [Related]
12. Inhibition of growth of experimental prostate cancer with sustained delivery systems (microcapsules and microgranules) of the luteinizing hormone-releasing hormone antagonist SB-75. Korkut E, Bokser L, Comaru-Schally AM, Groot K, Schally AV. Proc Natl Acad Sci U S A; 1991 Feb 01; 88(3):844-8. PubMed ID: 1992476 [Abstract] [Full Text] [Related]
18. Down-regulation of pituitary receptors for luteinizing hormone-releasing hormone (LH-RH) in rats by LH-RH antagonist Cetrorelix. Halmos G, Schally AV, Pinski J, Vadillo-Buenfil M, Groot K. Proc Natl Acad Sci U S A; 1996 Mar 19; 93(6):2398-402. PubMed ID: 8637885 [Abstract] [Full Text] [Related]